The Food and Drug Administration has granted approval for the first flu vaccine utilizing mRNA technology. Moderna confirmed this development on Wednesday evening, marking a significant advancement in vaccine options for respiratory illnesses.
This new vaccine will be accessible to adults aged 50 and over who seek immunization against the flu. Moderna disclosed that the shot will likely be available at select retailers within the upcoming weeks.
The approval comes after discussions, including skepticism from figures like RFK Jr., regarding mRNA technology. Despite these controversies, the move forward indicates a growing acceptance and reliance on mRNA-based solutions for combating illnesses.
An image taken in 2024 at Moderna’s headquarters in Cambridge, Massachusetts, captured a researcher engaged in work related to mRNA vaccines. This image highlights the ongoing efforts in developing innovative vaccine technologies.
New Insights into Ovarian Cancer Origins 
Cyclospora Illness Linked to Contaminated Iceberg Lettuce 
Senate Confirms Dr. Erica Schwartz as New CDC Director Amid Viral Outbreaks 
Senate Confirms Erica Schwartz as CDC Leader Amid Concerns 
Fauci Faces Possible Contempt Charges 
Maine’s Maternity Care Crisis: A Fight for Essential Services